Supplementary Material for: Objective response and progression free survival contribute to prolong overall survival in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma.

  • Kazuto Tajiri (Contributor)
  • Kenichiro Tsukada (Contributor)
  • Yoshiharu Tokimitsu (Contributor)
  • Yuchi Motofuji (Contributor)
  • Kengo Kawai (Contributor)
  • Nozomu Muraishi (Contributor)
  • Aiko Murayama (Contributor)
  • Yuka Hayashi (Contributor)
  • Y. Shimizu (Contributor)
  • Ichiro Yasuda (Contributor)

Dataset

Description

Introduction: Atezolizumab plus bevacizumab (Atez/Bev) is a standard treatment for unresectable hepatocellular carcinoma (HCC) due to its good anti-tumor and survival prolongation effects. Post-progression survival (PPS) has been reported to be a great contributor in the treatment with tyrosine kinase inhibitors for unrecetable HCC. This study aimed to clarify the significance of progression-free survival (PFS) or PPS of Atez/Bev treatment for HCC. Methods: We analyzed the correlations of PFS and PPS with overall survival (OS) in studies of HCC patients treated with Atez/Bev and evaluated the contribution to OS in Atez/Bev treatment with patients at our institutions as clinical practice. Results: Analysis of 18 studies involving 2,937 patients treated with Atez/Bev found that PPS had a stronger correlation with OS (R2=0.872, p
Date made available2023
PublisherKarger Publishers

Access Dataset

Cite this